Arrowstreet Capital Limited Partnership boosted its stake in Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) by 81.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 150,150 shares of the company's stock after acquiring an additional 67,269 shares during the quarter. Arrowstreet Capital Limited Partnership owned 0.92% of Sensus Healthcare worth $1,039,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also modified their holdings of SRTS. IFP Advisors Inc purchased a new position in Sensus Healthcare in the 4th quarter valued at $95,000. Geode Capital Management LLC raised its position in shares of Sensus Healthcare by 8.5% in the third quarter. Geode Capital Management LLC now owns 146,404 shares of the company's stock valued at $849,000 after buying an additional 11,525 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Sensus Healthcare in the fourth quarter worth about $189,000. XTX Topco Ltd boosted its position in Sensus Healthcare by 76.0% during the third quarter. XTX Topco Ltd now owns 31,530 shares of the company's stock worth $183,000 after acquiring an additional 13,619 shares during the last quarter. Finally, Sigma Planning Corp purchased a new stake in Sensus Healthcare during the 4th quarter valued at about $215,000. Hedge funds and other institutional investors own 25.30% of the company's stock.
Sensus Healthcare Stock Down 2.9 %
SRTS stock traded down $0.14 during midday trading on Tuesday, hitting $4.65. The company's stock had a trading volume of 222,723 shares, compared to its average volume of 308,829. The firm has a 50-day simple moving average of $4.93 and a 200-day simple moving average of $6.44. The firm has a market capitalization of $76.70 million, a P/E ratio of 11.63 and a beta of 1.11. Sensus Healthcare, Inc. has a 52-week low of $3.09 and a 52-week high of $9.33.
Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.09 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.01). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. On average, sell-side analysts expect that Sensus Healthcare, Inc. will post 0.32 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
SRTS has been the topic of several recent research reports. Lake Street Capital lowered their target price on Sensus Healthcare from $18.00 to $13.00 and set a "buy" rating on the stock in a report on Tuesday, March 11th. HC Wainwright reissued a "buy" rating and set a $12.00 target price on shares of Sensus Healthcare in a research note on Friday, April 4th.
Check Out Our Latest Research Report on Sensus Healthcare
About Sensus Healthcare
(
Free Report)
Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Further Reading
Before you consider Sensus Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sensus Healthcare wasn't on the list.
While Sensus Healthcare currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
